Zacks Investment Research Lowers Nabriva Therapeutics AG (NBRV) to Hold
Nabriva Therapeutics AG (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Other analysts have also issued research reports about the company. HC Wainwright assumed coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They issued a “buy” rating and a $16.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $17.00 price objective on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $15.89.
Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 6.94 on Wednesday. The company has a 50 day moving average price of $7.47 and a 200-day moving average price of $7.88. Nabriva Therapeutics AG has a 52-week low of $6.61 and a 52-week high of $10.69. The firm’s market cap is $147.52 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($6.25) by $5.75. Equities research analysts anticipate that Nabriva Therapeutics AG will post ($1.93) EPS for the current year.
Institutional investors have recently modified their holdings of the stock. Vivo Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the first quarter valued at about $28,239,000. Opaleye Management Inc. raised its position in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares during the period. Finally, Jackson Park Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the second quarter valued at about $195,000. 63.05% of the stock is currently owned by institutional investors and hedge funds.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.